Several mechanisms for cathepsin B’s contribution to cancer development were demonstrated with in vitro and in vivo models, and its ability to proteolytically interfere with the apoptotic pathway was proposed to be a significant aspect of its oncogenic potential (Aggarwal and Sloane, 2014). Here, CTSB is linked to cancer.